Toltrex(Tolterodine Tartrate)

Therapeutic Group: Urological


Toltrex 2: Each tablet contains Tolterodine Tartrate INN 2 mg


Tolterodine is a competitive, specific muscarinic receptor antagonist, which exhibits selectivity for the urinary bladder over salivary glands. One of the tolterodine metabolites (5-hydroxymethyl derivative) exhibits a pharmacological profile similar to that of the parent compound. In extensive metabolisers this metabolite contributes significantly to the therapeutic effect.


Toltrex is indicated for the treatment of overactive bladder with symptoms of urinary urgency, frequency, and/or urge incontinence.

Dosage & Administration

The recommended dose is 2 mg b.i.d. In the case of troublesome side-effects the dose may be reduced from 2 mg to 1 mg b.i.d.
The recommended dose is 1 mg b.i.d. for patients with impaired renal function, impaired liver function, or receiving concomitant ketoconazole or other potent CYP3A4 inhibitors.

Side Effects

Tolterodine may cause mild-to-moderate antimuscarinic effects, like dryness of the mouth, dyspepsia and reduced lacrimation.


Tolterodine should be used with caution in the patients at risk for urinary retention & decreased gastrointestinal motility, with impaired renal & hepatic function and with myasthenia gravis.

Use in Pregnancy & Lactation

There are no studies in pregnant women. Therefore, tolterodine should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. Use of tolterodine during lactation should be avoided since no data on excretion into breast milk in humans are available.

Drug Interaction

Ketoconazole, a potent inhibitor of CYP3A4, significantly increased plasma concentrations of tolterodine when co-administered to poor metabolisers. For patients receiving ketoconazole or other potent CYP3A4 inhibitors, the recommended total daily dose is 2 mg.

Over Dose

Treatment of overdosage with Tolterodine should consist of activated charcoal. Activated charcoal is usually most effective when administered within 1-hour of ingestion. Ipecac-induced emesis is not recommended, and dialysis is not likely to be of benefit as tolterodine is highly protein-bound.

Commercial Pack

Toltrex 2: Each box contains 3 blister strips of 10 tablets.